Guo Xiaoping, Zheng Haoyu, An Yiming, Song Yuemeng, Liu Tianqi, Zhou Zhengjie, Liu Chuangui, Wang Guoqiang, Wang Fang
Department of Pathogen Biology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China.
National and Local United Engineering R&D Center of Ginseng Innovative Drugs, Changchun 130021, China.
Pharmaceuticals (Basel). 2025 Aug 18;18(8):1216. doi: 10.3390/ph18081216.
Coronavirus disease 2019 (COVID-19) has been a global pandemic since 2019, but effective therapeutic treatments for it remain limited. Shuqing Granule (SG) is a traditional Chinese medicine containing ingredients such as indirubin, shinpterocarpin, naringenin, and quercetin. It exhibits anti-inflammatory and antiviral activities as well as broad-spectrum antiviral effects, yet its potential role in the treatment of COVID-19 remains unclear. This study thus aimed to explore the therapeutic effects of SG on COVID-19, with a focus on its potential anti-SARS-CoV-2 activity linked to these bioactive ingredients. The potential therapeutic ability of SG was investigated by combining network pharmacology, molecular docking, and experimental verification. First, key ingredients in SG and their corresponding targets, as well as COVID-19-related targets, were identified. Then, enrichment analyses were performed to highlight potential key pathways. Additionally, molecular docking was conducted to assess the binding capacity of the key ingredients to ACE2. Finally, experiments such as Western blot and ELISA were conducted to verify the effect of SG. The results showed that 15 key ingredients such as quercetin in SG could affect overlapping targets such as RELA. Molecular docking results showed that key ingredients in SG, such as isoliquiritigenin, formononetin, shinpterocarpin, indirubin, naringenin, kaempferol, and 7-Methoxy-2-methylisoflavone, might bind to angiotensin-converting enzyme II (ACE2)-a critical receptor in the process of COVID-19 infection-thereby exerting antiviral effects. Experiments such as Western blot and ELISA further demonstrated that SG could reduce inflammation induced by the SARS-CoV-2 S1 protein by 50%. This effect might be achieved by downregulating ACE2 expression by 1.5 times and inhibiting the NF-κB signaling pathway. This study confirmed that SG has potential as a candidate for COVID-19 treatment. It also provided a new approach for the application of traditional Chinese medicine in combating the virus.
自2019年以来,新型冠状病毒肺炎(COVID-19)已成为全球大流行疾病,但针对该疾病的有效治疗方法仍然有限。舒清颗粒(SG)是一种中药,含有靛玉红、苏木精、柚皮素和槲皮素等成分。它具有抗炎和抗病毒活性以及广谱抗病毒作用,但其在治疗COVID-19中的潜在作用仍不清楚。因此,本研究旨在探索SG对COVID-19的治疗效果,重点关注其与这些生物活性成分相关的潜在抗SARS-CoV-2活性。通过结合网络药理学、分子对接和实验验证来研究SG的潜在治疗能力。首先,确定了SG中的关键成分及其相应靶点以及与COVID-19相关的靶点。然后,进行富集分析以突出潜在的关键途径。此外,进行分子对接以评估关键成分与ACE2的结合能力。最后,进行蛋白质免疫印迹和酶联免疫吸附测定等实验以验证SG的效果。结果表明,SG中的槲皮素等15种关键成分可影响RELA等重叠靶点。分子对接结果表明,SG中的关键成分,如异甘草素、芒柄花素、苏木精、靛玉红、柚皮素、山奈酚和7-甲氧基-2-甲基异黄酮,可能与血管紧张素转换酶II(ACE2)结合,ACE2是COVID-19感染过程中的关键受体,从而发挥抗病毒作用。蛋白质免疫印迹和酶联免疫吸附测定等实验进一步证明,SG可将SARS-CoV-2 S1蛋白诱导的炎症降低50%。这种效果可能是通过将ACE2表达下调1.5倍并抑制NF-κB信号通路来实现的。本研究证实SG有潜力成为COVID-19治疗的候选药物。它还为中药对抗病毒的应用提供了一种新方法。